Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sucrose; butylated hydroxytoluene; croscarmellose sodium; microcrystalline cellulose; gelatin; medium chain triglycerides; colloidal anhydrous silica - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals inc - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies ( 14.1 ).] alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis [see clinical studies ( 14.2 )] . alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis [ see clinical studies ( 14.3 )] . alendronate sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies ( 14.4 )] . alendronate sodium tablets are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's disease of bone

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [ see clinical studies (14.1).] alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis [ see clinical studies (14.2)]. alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies ( 14.3)]. alendronate sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies ( 14.4)]. alendronate sodium tablets are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's disease of bon

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; magnesium stearate; butylated hydroxytoluene; gelatin; medium chain triglycerides; sucrose - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.14 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sucrose; gelatin; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; butylated hydroxytoluene; povidone; medium chain triglycerides - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Canada - English - Health Canada

qd pharmaceuticals ulc - alendronic acid (alendronate sodium trihydrate) - tablet - 70mg - alendronic acid (alendronate sodium trihydrate) 70mg - bone resorption inhibitors